ACTRN12618000112268已完成1 期
First-in-human study to investigate the skin tolerability of micro-projection array patches coated with inactivated split influenza virus haemagglutinin (HA) from A/Singapore/GP1908/2015 (A/Michigan/45/2015(H1N1)-like) vaccine in healthy volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •1.Aged 18-50 years (inclusive).
- •2.Subject has a Body Mass Index (BMI) within the range 18.0–30.0 kg/m²
- •3.Satisfactory medical assessment, with no clinically significant or relevant abnormalities in medical history, physical examination, vital signs and laboratory evaluation (haematology or biochemistry)
- •4.Adequate venous access in their left or right arms to allow collection of a number of blood samples.
- •5. Females of childbearing potential and males should either be sexually inactive (abstinent) for 14 days prior to screening and throughout the study or be using one of the following acceptable birth control methods:
- •a.Surgically sterile (hysterectomy and/or bilateral oophorectomy);
- •b.Surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study initiation);
- •c.IUD in place for at least 3 months;
- •d.Stable hormonal contraceptive for at least 3 months prior to study through completion of study;
- •e.Surgical sterilization (vasectomy) for male participants or for female participant’s partner at least 6 months prior to study
- •f.Condom for male participant together with effective contraception for their female partner.
- •6.Postmenopausal women must have had at least 12 months since their last menstrual period
- •7.Subject is able to communicate effectively with study personnel and is considered reliable, willing and cooperative in terms of compliance with the protocol requirements.
- •8.Subject is able and willing to provide written, personally signed and dated informed consent to participate in the study.
排除标准
- •1.Subject with birthmarks, tattoos, wounds, scars, moles, blemishes, heavy hair or other skin conditions (such as eczema) on forearms and upper arm regions (both arms) which could reasonably obscure application site reactions.
- •2.Subject with known chronic spontaneous urticaria / dermographism
- •3.Known anaphylactic hypersensitivity to a previous influenza vaccination or to eggs, neomycin, polymyxin B sulphate or any of the constituents or trace residues of the study vaccine.
- •4.Has received an influenza vaccine or has been diagnosed by a doctor as having influenza in the last 12 months.
- •5.Known history of Guillain-Barré syndrome.
- •6.Recent vaccination (within 30 days prior to enrolment) with any vaccine.
- •7.Known predisposition to keloid scar formation.
- •8.History of granulomatous diseases (especially sarcoidosis and granuloma annulare).
- •9.History of clinically significant gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or haematological disorders.
- •10.History of malignancy, other than non-melanoma skin cancer.
- •11.An active medical condition (which is deemed as clinically significant) that is under evaluation or treatment, or a recent illness, a chronic illness, an autoimmune disease or had major surgery within the last year.
- •12.History of Hepatitis B, Hepatitis C or HIV infection or clinical laboratory serology is positive for Hepatitis B surface antigen, Hepatitis C or HIV antibodies.
- •13.History of abnormal bleeding tendencies or thrombophlebitis unrelated to venepuncture or intravenous cannulation.
- •14.Receiving chronic treatment with immune-suppressive therapy (asthma inhalers and topical corticosteroids are permitted). All medications will be documented and reviewed for acceptance by the Investigator or a medically qualified nominee.
- •15.History of any psychiatric illness or psychological disorder which may impair the ability to provide written informed consent or participate in the study.
- •16.Subject has donated blood or plasma or clinically significant blood loss within 60 days prior to screening visit.
- •17.Subject is pregnant or breast-feeding.
- •18.A history of alcohol or drug abuse in the last 12 months or current alcohol consumption is >4 standard drinks (or equivalent) per day.
- •19.Use of any prescription medication (except for contraceptives) within 7 days, unless approved by the PI. All medications will be documented and reviewed for acceptance by the Investigator or a medically qualified nominee.
- •20.Use of any investigational drug or device within 30 days or 5 half-lives of the drug, whichever is longer, prior to the Day 1.
- •21.Previous exposure to the Nanopatch and its applicator as a participant in previous clinical studies.
研究者
相似试验
尚未招募
1 期
A study to evaluate the safety and tolerability of multiple formulations of an investigational transdermal patch in healthy volunteersAlzheimer's DiseaseACTRN12619000574145INC Research Australia Pty Ltd24
尚未招募
Unknown
A Human study to evaluate the effect on the skin health and safety of Vegetable Collagen(VC-H1)KCT0009307Global Medical Research Center100
已完成
不适用
Skin Primary Irritation Test in HumansKCT0004022Dermapro30
已完成
不适用
Human application study to confirm the skin health improvement effect and safety of ChlorellaKCT0007205Global Medical Research Center100
已完成
不适用
Pilot study to asses the dependence of skin autofluorescence (SAF) on skin color <br>and skin tissue characteristics in humans with dark skiafhankleijkheid meting van huidskleur1003502310003216NL-OMON43312niversitair Medisch Centrum Groningen12